文献速递血栓与止血

疫苗诱导的免疫性血小板减少症和血栓形成中抗血小板因子4抗体持续3年

Persistence of anti-platelet factor 4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis for 3 years.
PubMed 文献 · J Thromb Haemost · 2025-09-26

该研究随访加拿大30例疫苗诱导的免疫性血小板减少症和血栓形成(VITT)患者近3年,中位随访715天,发现65.2%患者抗血小板因子4抗体持续阳性,34.1%患者血小板活化抗体持续阳性,无复发性血栓事件,但8例持续血小板活化抗体患者中7例仍接受抗凝或抗血小板治疗。

要点

  • VITT患者抗PF4抗体可持续近3年,65.2%持续阳性,34.1%血小板活化抗体持续阳性。
  • 随访期间无复发性血栓事件。
  • 8例持续血小板活化抗体患者中7例仍接受抗凝或抗血小板治疗。

核心结论

  • VITT抗体可在部分患者中持续近3年,其中一部分保持体外激活血小板的能力。
  • VITT抗体持续的确切时长尚不清楚,其临床意义需持续监测和进一步评估。

研究设计与样本

  • 研究随访加拿大VITT患者队列(N=30),从初次就诊起近3年,系列检测抗PF4抗体水平(酶免疫法)及PF4-血清素释放试验中的血小板活化能力。
  • 中位最新随访时间为疫苗接种后715天(范围126-1065天)。

主要发现

  • Kaplan-Meier分析显示,65.2%的VITT患者抗PF4抗体持续阳性。
  • 34.1%的患者血小板活化性抗PF4抗体持续阳性。
  • 无复发性血栓事件;8例持续血小板活化性抗PF4抗体患者中7例(87.5%)仍接受抗凝或抗血小板治疗。

局限性

  • VITT抗体持续的确切时长尚不清楚。
  • 抗体持续是否具有临床意义需持续监测和进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare and potentially life-threatening complication of adenoviral vector-based vaccines against SARS-CoV-2. In VITT, antibodies against platelet factor 4 (PF4; ie, CXCL4) cause platelet activation, which then leads to thrombocytopenia and thrombosis. VITT resembles the immune-mediated drug reaction of heparin-induced thrombocytopenia; however, unlike heparin-induced thrombocytopenia antibodies, which have been shown to be transient, VITT antibodies appear to persist for much longer. OBJECTIVE(S): To identify the clinical outcomes and laboratory testing features of VITT patients beyond the acute phase of disease. METHODS: In this study, we followed a Canadian cohort of VITT patients (N = 30) for nearly 3 years from their initial presentation and report serial testing for anti-PF4 antibody levels by enzyme immunoassay, as well as the ability to activate platelets in the PF4-serotonin release assay. The median latest follow-up time was 715 days (range, 126-1065) post-vaccination. RESULTS: Using Kaplan-Meier analysis, we found that 65.2% of VITT patients continued to test positive for anti-PF4 antibodies, and 34.1% of patients continued to test positive for platelet-activating anti-PF4 antibodies. There were no cases of recurrent thrombosis; however, 7/8 (87.5%) VITT patients with persistent platelet-activating anti-PF4 antibodies remained on anticoagulant or antiplatelet therapy. CONCLUSION: Our findings demonstrate that VITT antibodies can persist for nearly 3 years in some patients, and a proportion of those maintain the ability to activate platelets in vitro. The complete duration of VITT antibody persistence remains unknown, and whether this has clinical implications requires ongoing surveillance with further evaluation.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hack M, Arnold DM, Clare R, et al. Persistence of anti-platelet factor 4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis for 3 years. J Thromb Haemost. 2025. PMID: 41016475. doi:10.1016/j.jtha.2025.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。